SCCM Resource Library-Comparison of Factor Products for Treatment of Bleeding Related to Cardiac Surgery

Comparison of Factor Products for Treatment of Bleeding Related to Cardiac Surgery

Video Transcription

Video Summary

The study compared the efficacy and safety of low-dose recombinant factor VII and four-factor PCC in patients with uncontrolled bleeding related to cardiac surgery. The results showed that there was no significant difference in the need for packed red blood cell transfusions within six hours of factor product administration. However, the PCC group received higher volumes of blood products overall. Additionally, the PCC group had a higher incidence of acute kidney injury compared to the recombinant factor VII group. The study concluded that further research is needed to determine the optimal dosing and timing of these factor products.

Asset Subtitle

Procedures, Hematology, 2023

Asset Caption

Type: star research | Star Research Presentations: Cardiovascular (SessionID 30001)

Meta Tag

Content Type Presentation

Knowledge Area Procedures

Knowledge Area Hematology

Membership Level Professional

Membership Level Select

Tag Coagulation

Tag Surgery

Year 2023

Keywords

efficacy

safety

uncontrolled bleeding

factor products

cardiac surgery

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.